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Abstract 
Chemokine (C-X-C motif) receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in 
several types of human cancer including multiple myeloma (MM). Proof-of-concept of CXCR4-directed 
radionuclide therapy in MM has recently been reported. This study assessed the diagnostic performance 
of the CXCR4-directed radiotracer [68Ga]Pentixafor in MM and a potential role for stratifying patients 
to CXCR4-directed therapies.  
Thirty-five patients with MM underwent [68Ga]Pentixafor-PET/CT for evaluation of eligibility for 
endoradiotherapy. In 19/35 cases, [18F]FDG-PET/CT for correlation was available. Scans were 
compared on a patient and on a lesion basis. Tracer uptake was correlated with standard clinical 
parameters of disease activity.  
[68Ga]Pentixafor-PET detected CXCR4-positive disease in 23/35 subjects (66%). CXCR4-positivity at 
PET was independent from myeloma subtypes, cytogenetics or any serological parameters and turned 
out as a negative prognostic factor. In the 19 patients in whom a comparison to [18F]FDG was available, 
[68Ga]Pentixafor-PET detected more lesions in 4/19 (21%) subjects, [18F]FDG proved superior in 7/19 
(37%). In the remaining 8/19 (42%) patients, both tracers detected an equal number of lesions. 
[18F]FDG-PET positivity correlated with [68Ga]Pentixafor-PET positivity (p=0.018). 
[68Ga]Pentixafor-PET provides further evidence that CXCR4 expression frequently occurs in advanced 
multiple myeloma, representing a negative prognostic factor and a potential target for myeloma specific 
treatment. However, selecting patients for CXCR4 directed therapies and prognostic stratification 
seem to be more relevant clinical applications for this novel imaging modality, rather than diagnostic 
imaging of myeloma. 
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Introduction 
Multiple myeloma (MM) accounts for 
approximately 1% of all cancers and around 10% of 
hematological malignancies [1, 2]. Although overall 
survival has improved over the last decade, based on 
the availability of various novel drugs and treatment 









Chemokine (C-X-C motif) receptor 4 (CXCR4) 
has been described to play a pivotal role in tumor 
growth and progression, tumor invasiveness and 
metastasis [3]. Overexpression of the receptor has 
been reported in more than 30 different types of 
cancer [4-7]. CXCR4 activation has been shown to 
correlate with MM-related bone disease [8, 9]. 
Additionally, the interplay between receptor and its 
ligand stromal derived factor 1 (SDF-1α/CXCL12) 
serves as a stimulator of plasma cell proliferation [4]. 
Recently, a radiolabelled CXCR4-ligand 
([68Ga]Pentixafor) for PET imaging has been 
developed [10, 11]. Dosimetry and proof-of-concept 
for visualization of CXCR4-expression could be 
demonstrated in patients with multiple myeloma and 
other hematologic and solid malignancies [12-15]. A 
pilot study further proved the feasibility of 
CXCR4-directed radionuclide therapy as a novel 
treatment approach for MM [16].  
In this study, we aimed to further evaluate the 
performance of [68Ga]Pentixafor-PET/CT in 
comparison to [18F]FDG-PET/CT, serving as 
reference. Additionally, we correlated in-vivo CXCR4 
expression with cytogenetics and serum markers of 
diseases activity. 
Materials and Methods 
[68Ga]Pentixafor was administered on a 
compassionate use base in compliance with §37 of the 
Declaration of Helsinki and The German Medicinal 
Products Act, AMG §13 2b and in accordance with the 
responsible regulatory body (Regierung von 
Oberfranken, Bavaria, Germany). All patients had 
exhausted all alternative treatment options and 
underwent CXCR4-directed imaging for 
endoradiotherapy evaluation. All subjects gave 
written informed consent prior to [68Ga]Pentixafor 
PET/CT. 
Subjects and study design 
35 patients (23 males, 12 females, age 44-82 y, 
mean, 62±8.5 y) with a history of MM were included. 
All patients had been pre-treated with a number of 
various chemotherapeutic drug regimens including 
novel agents such as bortezomib, lenalidomide and 
others. 28/35 subjects had undergone autologous 
stem cell transplantation (SCT) before. At the time 
point of PET/CT scanning, serum free 
immunoglobulin light chains (FLC; all patients) and 
the M gradient (all patients) were recorded. Serum 
chemistry including lactate dehydrogenase (LDH), 
albumin, creatinine (all patients) and 
β2-microglobulin (27/35 patients) were obtained. 
Additionally, interphase molecular cytogenetics 
based on fluorescence in situ hybridization (FISH) 
were available in 21/35 patients. Presence of del(17p), 
t(4;14), t(14;16), t(14;20) and chromosome 1 
abnormalities were considered as high-risk, whereas 
all other karyotypes were classified as standard risk. 
PET/CT imaging  
[68Ga]Pentixafor was prepared as previously 
described [17]. In short, all syntheses were performed 
in a fully automated, GMP-compliant procedure 
using a GRP® module (SCINTOMICS GmbH, 
Germany) equipped with a disposable single-use 
cassette kit (ABX, Germany). The eluate (68Ga3+ in 0.6 
M HCl) of a 68Ge/68Ga-generator (iThemba Labs, 
Faure, South Africa) was transferred to a cation 
exchange cartridge, eluted with 5 N NaCl, added to a 
solution of 40 µg Pentixafor (Scintomics, 
Fürstenfeldbruck, Germany) in HEPES-buffer and 
heated for 6 minutes at 125 °C. The product was 
immobilized on a SepPak C18 cartridge, washed with 
water und eluted with ethanol/water 50/50. The 
eluate was passed through a sterile filter (0.22 µm) 
into a sterile vial und diluted with phosphate buffer 
solution to a total volume of 15 mL. Radiochemical 
purity was determined by gradient high performance 
liquid chromatography and thin-layer 
chromatography. Additionally, the product was also 
tested for ethanol content, pH, radionuclide purity, 
sterility, and endotoxins. 
[18F]FDG was synthesized in house with a 16 
MeV Cyclotron (GE PETtrace 6; GE Healthcare, 
Milwaukee, USA).  
All PET scans were performed on a dedicated 
PET/CT scanner (Siemens Biograph mCT 64; Siemens 
Medical Solutions, Germany) within two weeks. 
Before acquisition of [18F]FDG-PET/CT scans (19/35 
patients), patients fasted for at least 6 h prior to 
injection of [18F]FDG. Blood glucose levels were < 160 
mg/dl. Prior to [68Ga]Pentixafor PET/CT imaging (all 
patients), no fasting was necessary. Imaging was 
performed after a median of 60 minutes (range, 55-64 
minutes) after injection of 43 to 165 MBq (median, 133 
MBq) of [68Ga]Pentixafor and 256 to 340 MBq (median, 
299 MBq) of [18F]FDG, respectively. Corresponding 
CT low-dose scans for attenuation correction were 
acquired using a low-dose protocol (20 mAs, 120 keV, 
a 512 × 512 matrix, 5 mm slice thickness, increment of 
30 mm/s, rotation time of 0.5 s, and pitch index of 0.8) 
including the base of the skull to the proximal thighs. 
Consecutively, PET emission data were acquired in 
three-dimensional mode with a 200 × 200 matrix with 
2–3 min emission time per bed position. After decay 
and scatter correction, PET data were reconstructed 
iteratively with attenuation correction using a 
dedicated software (Siemens Esoft, Siemens, 
Erlangen, Germany). 






For [18F]FDG, criteria to define lesions as 
PET-positive were applied according to Zamagni et al. 
[13]. For [68Ga]Pentixafor, lesions were visually 
determined as focally increased tracer retention as 
compared to surrounding normal tissue or 
contralateral structures. Presence and number of 
intra- and extramedullary (EMD) disease as well as 
location of lesions were recorded. Analysis both on a 
patient and a lesion basis was performed. SUVmax of 
the hottest intra- and extramedullary lesion was 
measured.   
Statistical analysis 
Statistical analyses were performed using PASW 
Statistics software (version 22.0; SPSS, Inc. Chicago, 
IL). Quantitative values were expressed as mean ± 
standard deviation or median and range as 
appropriate. Comparisons of related metric 
measurements were performed using 
Wilcoxon-signed rank test. The Chi square- or Fisher 
exact test was conducted for comparison of frequency 
data between independent subgroups. For bivariate 
correlation analyses, Spearman or Pearson correlation 
coefficients were calculated. All statistical tests were 
performed two-sided and a p-value < 0.05 was 
considered to indicate statistical significance. No 




All patients presented with advanced, active 
MM. High-risk cytogenetics were documented in 
10/21 (47.6%) subjects. Serum FLC ranged from 0.5 to 
18.556.0 mg/l (median, 395.8), ß2m from 1.8 to 33 
(median, 5.7) and M gradients from 0 to 52.7 g/dl 
(median, 0). Albumin levels were decreased (<3.5 
g/dl) in 8/35 (22.9%) patients. Serum creatinine was 
increased (>1.2 mg/dl) in 13/35 (37.1%) subjects and 
LDH in 17/35 (48.6%). Patients´ characteristics are 
summarized in Table 1. 
Imaging results 
[68Ga]Pentixafor-PET was visually positive in 
23/35 patients (65.7%, example given in Figure 1). In 
the remaining 12 subjects with serologically active 
disease, no relevant expression of CXCR4 could be 
recorded.  
8/23 (34.8%) CXCR4-positive patients presented 
with disease confined to the bone marrow 
compartment (intramedullary lesions), 13/23 (56.5%) 
patients suffered from both intra- and extramedullary 
disease and the remaining 2/23 (8.7%) patients had 
exclusively extramedullary MM manifestations 
(EMD). Hence, 65.2% (15/23) of [68Ga]Pentixafor- 
PET-positive patients presented with extramedullary 
manifestations. Regarding EMD, soft tissue 
involvement was most commonly seen (12/15, 
80.0%), followed by manifestations in lymph nodes 
(7/15, 46.7%), liver (3/15, 20.0%), testis (2/15, 13.3%) 
and lungs (1/15, 6.7%). Regarding intramedullary 
MM, 18/21 CXCR4-positive patients (85.7%) showed 
involvement of the appendicular skeleton, with 11/18 
(61.1%) also presenting with EMD.  
CXCR4 negativity turned out as a positive 
prognostic factor: In the group of patients with a 
negative [68Ga]Pentixafor-PET scan, median OS was 
not reached (vs. 181±41 d in PET-positive patients; 
p=0.022, Figure 2). TTP tended to be longer in 
[68Ga]Pentixafor-PET negative subjects (123±42 d vs 
53±5 d; p=0.11). 
 
Table 1: Patients´ characteristics. 
















1 m 69 IgG λ 26 27.75 287.0 (λ) other yes 
2 m 61 IgG κ 16 6.41 47.8 (κ) other yes 
3 m 50 light chain λ 37 0 1880.0 (λ) other yes 
4 m 56 IgA κ 27 28.24 7.0 (κ) other yes 
5 f 60 IgG κ 120 14.07 390.0 (κ) n/a yes 
6 m 78 light chain κ 91 0 469.6 (κ) n/a no 
7 m 72 IgG κ 11 0 18556.0 (κ) n/a no 
8 f 64 IgG κ 128 52.65 1426.9 (κ) other yes  
9 f 69 IgG κ 37 44.46 263.5 (κ) high-risk no 
10 m 74 IgG κ 61 22.41 611.5 (κ) n/a yes 
11 m 82 IgA κ 55 0 23.0 (κ) other no 
12 f 64 IgG λ 85 0.97 0.4 (λ) high-risk yes 
13 m 51 light chain λ 57 0 2644.0 (λ)  other yes 
14 m 66 light chain λ 33 0 5260.0 (λ) other no 
15 m 65 IgG κ 160 0 4061.0 (κ) other yes 
16 f 66 light chain κ 67 0 1349.0 (κ) n/a yes 
17 m 53 IgG κ 47 6.16 74.5 (κ) n/a yes 
18 f 58 light chain λ 57 0 102.7 (λ) n/a yes 
19 m 65 light chain κ 106 0 14.7 (κ) n/a yes 
20 m 66 IgG κ 22 1.,57 270.5 (κ) n/a yes 
21 f 65 IgA κ 12 0 2387.0 (κ) high-risk yes 
22 f 53 light chain κ 121 0 99.7 (κ) other yes  
23 f 62 light chain κ 54 0 5243.0 (κ) n/a yes 
24 f 57 IgG κ 61 26.97 752.4 (κ) high-risk yes 
25 m 65 IgA κ 100 32.65 401.6 (κ) high-risk yes 
26 f 58 IgA κ 59 36.87 1306.0 (κ) n/a yes 
27 m 62 IgG λ 195 49.24 139.6 (λ) other yes 
28 m 67 light chain λ 146 0 1165.9 (λ) n/a yes 
29 m 67 IgG κ 38 33.02 5008.0 (κ) high-risk yes 
30 m 44 asecetory 16 0 n/a n/a yes 
31 f 58 light chain κ 12 0 37.6 (κ) high-risk 0 
32 m 73 IgA λ 113 13.19 4696.0 n/a 0 
33 m 65 IgA λ 9 0 123.8 high-risk yes 
34 m 52 IgG κ 75 0 77.4 (κ) high-risk yes 
35 m 48 IgG κ 17 n/a n/a high-risk yes 
 






Figure 1: Display of a patient (patient #33) with MM Ig A λ and rising free serum light chains. [68Ga]Pentixafor-PET depicts intense tracer uptake in multiple 
intramedullary (stars) as well as extramedullary (arrows) lesions. 
 
Figure 2: Prognostic impact of [68Ga]Pentixafor-PET/CT positivity, presence of [68Ga]Pentixafor PET/CT-positive lesions in the appendicular skeleton and EMD on 
overall survival. Given are the cumulated survival (y-axis) and the overall survival (in days; x-axis) for various scenarios of CXCR4+ PET/CT findings. 
 
Number and location of intramedullary lesions 
Of the 21/35 (60.0%) patients who presented 
with focal intramedullary PET-positive lesions, 
[68Ga]Pentixafor-PET detected less than 20 
intramedullary lesions in 8/21 (38.1%) and more than 
20 intramedullary lesions in 13/21 (61.9%) patients. 
Of note, 8/13 (61.5%) subjects with extensive 
intramedullary disease also exhibited extramedullary 
myeloma involvement. 
Presence of [68Ga]Pentixafor-PET positive 
intramedullary lesions tended to be associated with 
shorter OS (181±53 d vs. OS not reached in patients 
without IMD; p=0.085) and TTP (58±7 d vs. 102±31 d; 
p=0.311). A rising number of intramedullary lesions 
had no significant impact on TTP or OS. Interestingly, 





involvement of the appendicular skeleton proved to 
be associated with significantly shorter OS (181±119 d 
vs. 470±178 d; p=0.038; Figure 2) and TTP (58±6 d vs. 
102±23 d; p=0.159). 
Number and location of extramedullary 
lesions 
Presence of CXCR4-positive EMD was 
associated with both shorter TTP (49±4 d vs. 105±23 d 
in EMD negative patients; p=0.018) and OS (169±36 d 
vs. not reached; p<0.0001; Figure 2). Of note, the 
number of EMD lesions had a prognostic value, 
regarding both TTP (p= 0.055) and OS (p<0.001): 
Patients with <20 lesions (8/15; 53.3%) patients had a 
significantly better outcome (TTP 49±8 d; OS: 169±25 
d) than those with >20 focal lesions (7/15; 46.7%) (TTP 
41±39 d; OS 50±51 d). 
Comparison to [18F]FDG: patient-based 
analysis 
In the 19 subjects undergoing both 
[68Ga]Pentixafor- and [18F]FDG-PET, both 
[68Ga]Pentixafor and [18F]FDG were positive in 11/19 
(57.9%) patients; 4/19 (21.1%) patients were negative 
in both scans (Table 2). [18F]FDG-PET positivity 
correlated with [68Ga]Pentixafor-PET positivity 
(p=0.018). 3/19 (15.8%) patients were missed by 
[68Ga]Pentixafor-PET (CXCR4-/FDG+; patients # 4, 21, 
31). Of these patients, #21 and #31 presented with 
extensive IMD (>20 FL) with involvement of the 
appendicular skeleton. Additionally, patient #21 had 
EMD with soft tissue involvement. MM was confined 
to the bone marrow (<10 FL) in patient #4. The single 
patient (1/19, 5.3%; patient #22) who was missed by 
FDG-PET (CXCR4+/FDG-) presented with extensive 
IMD in the appendicular skeleton (>20 lesions; 
Figure 3).  
Comparison to [18F]FDG: lesion-based analysis 
Imaging with [68Ga]Pentixafor demonstrated 
more focal lesions than FDG in 4/19 patients (21.1%), 
whereas FDG identified more focal lesions in 7/19 
cases (36.8%) with 3/7 (42.9%) being CXCR- and the 
remainder presenting with a mixture of both CXCR4+ 
and CXCR4- disease.  
 
Table 2: Diagnostic Performance of [18F]FDG and 
[68Ga]Pentixafor (n=19). 
 [18F]FDG [68Ga]Pentixafor 
patient-based analysis   
PET-positive patients 73.7% 57.9% 
appendicular skeleton 47.4% 42.1% 
EMD 52.6% 52.6% 
LN involvement 21.0% 15.8% 
soft tissue involvement 42.1% 42.1% 
   
lesion-based analysis   
<20 FL 63.2% 73.7% 
> 20 FL 36.8% 26.3% 
total no. EMD FL 73 60 
Given are the positive-findings of the patient-based and lesion-based analysis of 
[68Ga]Pentixafor- and [18F]FDG-PET/CT, respectively. EMD = extramedullary 
disease; FL = focal lesion; LN = lymph node. 
 
 
Figure 3: Example of heterogeneity of [18F]FDG uptake and CXCR4 expression. Display of two patients with MM LC κ (patient #22) and MM Ig G κ (patient #34), 
respectively. Both patients present with metabolically completely different forms of disease. 





In the remaining 8 patients, an equal number of 
MM manifestations (identical lesions) were detected 
with both tracers. Most of the lesions exclusively 
identified by [18F]FDG located at extramedullary sites 
(7/7; 100%) predominantly in the soft tissue (4/7, 
57.1%) and in the appendicular skeleton (4/7; 57.1%).  
Most lesions exclusively identified by 
[68Ga]Pentixafor located at EMD sites in 2/3 subjects 
(with 2/3 [66.7%] in soft tissue und 1/3 [33.3%] in 
lymph nodes) and at the peripheral bone in the 
remaining patients. However, in one of these patients 
(patient #13), 2 pulmonary lesions (identified by 
[18F]FDG) were missed with [68Ga]Pentixafor. 
SUVmax of the hottest CXCR4 positive 
intramedullary lesions ranged from 4.1 to 57.4 
(median, 16.4), maximum uptake of the hottest 
CXCR4 positive extramedullary lesion from 5.0 to 67.1 
(median, 14.9). In comparison, SUVmax of the hottest 
intramedullary lesions in FDG images ranged from 
3.8 to 40.1 (median, 11.6), maximum FDG-uptake of 
the hottest extramedullary lesion from 5.0 to 37.7 
(median, 9.0). OS and TTP did not differ significantly 
if patients were stratified based on the median uptake 
of CXCR4- and FDG-positive intra- and 
extramedullary lesions. 
Correlation of imaging parameters with 
laboratory findings and cytogenetics 
[68Ga]Pentixafor-PET positivity was independent 
from all laboratory parameters investigated including 
LDH, albumin, creatinine, ß2M, M gradient or the 
level of free serum light chains as well as the 
cytogenetic risk profile and myeloma type.  
Discussion 
This is one of the first investigations indicating 
that expression of the chemokine receptor 4 (CXCR4) 
is a frequent event in multiple myeloma (MM) and 
can be non-invasively assessed by PET/CT and the 
CXCR4-directed radiopharmaceutical [68Ga]Pentixa-
for. About two-thirds of patients with advanced 
disease show multiple, CXCR4-expressing myeloma 
lesions. Moreover, previously unknown manifestation 
sites could be visualized in 21% of patients using this 
innovative imaging modality. This result is in line 
with a recent in-vitro analysis reporting CXCR4 
overexpression on the cell membrane of myeloma 
cells in 56% of cases [12].  
In our cohort, CXCR4-positivity was 
independent from myeloma subtype, M protein and 
free serum light chain levels or presence of high-risk 
cytogenetics. Of note, CXCR4 expression of MM 
proved as a significant predictor of shorter TTP and 
OS. As expected, presence and extent of CXCR4+ EMD 
was associated with pronouncedly reduced survival.  
In comparison to [18F]FDG serving as reference, 
[68Ga]Pentixafor-PET proved superior or equal to 
[18F]FDG regarding sensitivity for detecting MM 
lesions in 63% of cases. Interestingly, 3/19 (16%) 
patients were CXCR4-negative despite metabolically 
active disease, as identified by FDG-PET. In the 
remaining 4/19 (21%) subjects receiving imaging with 
both PET tracers, an intra-individual heterogeneity of 
receptor expression was noted with a mixture of both 
CXCR4+ and CXCR4- lesions. The biologic 
implications of this finding are not fully understood 
yet. One hypothesis speculated on potential 
inferiority of [68Ga]Pentixafor-PET in extramedullary 
disease due to reduced CXCR4 expression and its 
critical role in cell homing [18, 19]. Another recent 
publication hinted at a special role of CXCR4 in the 
acquisition of an epithelial-to-mesenchymal 
transition-like phenotype, which promotes MM cell 
dissemination [20].  
Given the fact that metabolic PET tracers 
including [11C]methionine, [11C]acetate and/or 
[11C]choline have been shown to be more sensitive 
than [18F]FDG [21-24], intra-individual differences of 
lesional chemokine receptor expression may even be 
more pronounced and should be assessed in direct 
head-to-head comparison trials (including biopsy 
samples of lesions with divergent uptake of the 
various tracers).  
Regarding visualization of extramedullary 
disease in general, both [68Ga]Pentixafor and [18F]FDG 
performed equally well. Interestingly, we were able to 
identify patients with exclusively [18F]FDG- as well as 
[68Ga]Pentixafor-avid extramedullary disease, 
respectively. Positivity for CXCR4, especially at EMD 
sites, proved to be as powerful a prognostic factor as 
[18F]FDG. Since the prognostic value of metabolic PET 
tracers like [11C]methionine or [11C]choline has not 
been established yet, a combination of different 
makers of glucose and amino acid metabolism as well 
as receptor surface expression might yield new 
insights into myeloma biology and should preferably 
be combined with histological analysis of genetic 
profiles [25]. 
In our cohort, the majority of heavily pre-treated 
patients qualified for CXCR4-directed therapy with a 
therapeutic counterpart allowing for labelling with 
both α- and β-emitters (90Y- or 177Lu-labelled 
Pentixather). Proof-of-concept in advanced stage MM 
patients could recently be demonstrated by our group 
[16]. Of note, CXCR4-directed treatment is only 
performed if the whole tumor cell compartment can 
be targeted by endoradiotherapy (ERT). Since 
pronounced intraindividual heterogeneity of receptor 
expression in different lesions can occur, we generally 
obtain an additional [18F]FDG-PET scan as reference 





for viable myeloma lesions and to exclude 
CXCR4-negative lesions which cannot be effectively 
treated by ERT. A prospective, multi-center trial in 
Germany will further evaluate the feasibility and 
benefit of radionuclide therapy in MM (COLPRIT, 
Eudra-CT 2015-001817-28). Additionally, anti-CXCR4 
therapies using non-radioactive agents, such as 
BMS-936564/MDX-1338, a fully human anti-CXCR4 
antibody, are currently under clinical investigation 
[26]. Given the increasing significance of multi-modal 
treatment approaches, combinations of novel agents, 
conventional chemotherapy or other receptors which 
are highly expressed in MM (e.g. CD38, SLAMF7, 
CD40) and radionuclide based therapies can be 
speculated on to yield synergistic effects and raise the 
hope for even more effective individualized treatment 
in the future. Yet, little is known about the influence 
of conventional chemotherapeutic drugs and/or 
novel agents on CXCR4 surface expression and 
regulation. Initiation of potent treatment regimens can 
rapidly downregulate CXCR4 and thereby severely 
hamper receptor-directed therapies [15]. Further 
analysis of regulators depressing or enhancing 
CXCR4 surface density is therefore urgently needed.  
The data presented have several limitations. In 
this cohort, [68Ga]Pentixafor-PET/CT imaging has 
been performed on a compassionate use base. Hence, 
this study has to be considered as a retrospective 
analysis, which comprises only a limited number of 
patients and is –due to its retrospective nature- prone 
to selection bias. Furthermore, not all patients 
received imaging with both radiotracers, preventing a 
more detailed comparison of the performance of 
[68Ga]Pentixafor compared to the clinically used 
radiotracer [18F]FDG. Also, not all positive MM 
lesions, especially extramedullary manifestations, 
were histologically proven. Therefore, there might be 
a false positive rate, e.g. regarding lymph node 
involvement. Distinct biological features of MM 
lesions presenting as CXCR4+/FDG- and vice versa 
were not investigated. It is not clear if – and to which 
extent – individual treatment decisions based of 
PET/CT imaging might have influenced patients’ 
overall prognosis. It can be hypothesized that 
switching a patient to a more intensive treatment 
regimen based on PET/CT findings might have 
resulted in more favourable outcomes. 
Treatment-induced bias due to heterogeneous 
treatments at relapse cannot be excluded in this series 
and may account for some of the prognostic 
differences that were found. The prognosis of lesions 
displaying high [68Ga]Pentixafor and low [18F]FDG 
uptake and how these lesions respond to current 
treatments has not been clarified yet. Further 
prospective studies also regarding the prognostic 
value of CXCR4-expressing disease in terms of 
therapy monitoring are highly warranted. 
In conclusion, [68Ga]Pentixafor-PET enables 
non-invasive detection of CXCR4 expression which 
occurs frequently in multiple myeloma. Our data 
suggest that CXCR4 expression represents a negative 
prognostic factor and is a potential target for myeloma 
specific treatment. Additionally, in a significant 
proportion of patients (21%) previously unknown 
myeloma lesions have been detected. Currently, 
selecting patients for CXCR4 directed therapies and 
prognostic stratification seem to be more relevant 
clinical applications than diagnostic imaging of 
myeloma.  
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